Leukemia

In a recent study, Blincyto (blinatumomab) had longer survival rates than standard chemotherapy for certain patients with ALL.

As Ed completes his final chemo cycle, he loses a friend.

More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.

Inotuzumab ozogamicin was granted a priority review designation for patients with relapsed or refractory ALL.

A supplemental biologics license application was filed for Blincyto to be approved for certain patients with ALL.

There is a need for more targeted clinical trials for patients with ALL, since many of them have Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia.

Group exercise programs are beneficial to survivors of cancer, and can offer motivation from peers to continue living a healthy lifestyle.

Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.

Many patients with cancer do not qualify for clinical trials because of comorbidities or other health problems. However, a recent study found that many of these patients can actually benefit from trials.

Several trials testing vadastuximab talirine for use in patients with AML were recently halted, according to the drug's manufacturer.

Recent studies found that for certain patients with CML, it is possible to safely reduce or stop TKI treatment.

CTL019, a CAR T-cell therapy, had a high response rate for young patients with relapsed/refractory ALL in a recent phase 2 study.

Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.

The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.

Through music, Christian Hoff shares his message of hope for patients and survivors of cancer.

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia.

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.

Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.

By mitigating some of the financial burdens, The Leukemia & Lymphoma Society helps patients better stick to treatment regimens.

The Beat AML trial just launched, and researchers are hoping it will find better treatment for patients with acute myeloid leukemia.

Targeted drugs known as TKIs have improved the prognosis for patients with chronic myeloid leukemia.

Subsets of patients with acute lymphoblastic leukemia are getting more personalized care.

Patients with CML who are insured by Medicare are choosing to delay potentially life-saving treatment due to high costs.

Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.

There are now more personalized treatment options for patients with CLL.

The FDA has approved Blincyto (blinatumomab) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.

Pracinostat was granted a breakthrough therapy designation by the FDA for use in some patients with AML.

Researchers are hoping to harness the leukemia-killing antibodies made by cured AML patients to treat others with the disease.